Bibliography
- Wegener G, Rujescu D. The current development of CNS drug research. Int J Neuropsychopharmacol 2013;16:1687-93
- Witchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsycopharmacol 2011;21:655-79
- Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-78
- Barbui C, Girlanda F, Ay E, et al. Implementation of treatment guidelines for specialist mental health care. Cochrane Database Syst Rev 2014;1:CD009780
- Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 2009;42:94-107
- Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 2014;28:387-94
- Hiemke C, Baumann P, Bergmann N, et al. AGNP consensus guideline for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195-235
- Hiemke C, Shams M. Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 2013;10:46-53
- Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
- Manchanda R, Chue P, Malla A, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry 2013;58(Suppl 1):5S-13S
- Ceskova E, Vrzalova M. Optimization of psychopharmacotherapy in schizophrenia (Optimalizace farmakoterapie schizofrenní poruchy). Psychiatrie Pro Praxi 2012;13:156-9
- Kirchheiner J, Rodriguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 2009;23:181-91
- Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP450 Pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 2013;149:1-14
- Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;7:248-54
- Andrade C. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins. Bipolar Disord 2013;15:813-23